

Corneal Collagen Cross-Linking Study
Web Site Upload for Minnesota Eye Consultants, P.A

STUDY TITLE: Safety and Effectiveness of the VEGA UV-A System for Corneal Collagen Cross-Linking in Eyes with Post-Refractive Corneal Ectasia

At present time, we are pleased to inform you that Minnesota Eye Consultants is conducting a clinical research study sponsored by Topcon Medical Systems, Inc. to evaluate an investigational treatment for corneal ectasia. The investigational treatment is known as corneal collagen cross-linking (CXL). CXL uses riboflavin (vitamin B2) and a UVA light source. It is designed to help improve or slow the progression of your corneal condition and vision loss.

This treatment will cause a reaction in the eye that will hopefully strengthen the fibers that make up the cornea. Up to 120 subjects will take part in this study. If you qualify and choose to enroll, you will be randomly assigned to one of two groups; a treatment group or a control group. The treatment group will undergo riboflavin and UVA light treatment. The control group will undergo riboflavin only treatment. You have an equal chance (1 in 2 or 50% chance) of being assigned to either group.

If your eye is first assigned to the control (riboflavin only) group, you can decide to enroll your other eye in an extension study after one month to be treated with the riboflavin and UV light. The eye that was initially randomized to the control treatment may enter the extension study to be treated following a 6-month observation period.

Visit Requirements

- An evaluation to determine eligibility
- Procedure
- Six study-related post-procedure exams at 1-day, 1-week, 1-month, 3-months, and 6-months

For more information, please contact the Minnesota Eye Consultants' clinical research department via email at research@mneye.com or call (612) 813-3607 and leave a message stating you are interested in the "Corneal Collagen Cross-Linking Study". A research department staff member will return your call.